AvenCell
PrivateLast Round
Grant
Jun 30, 2025
Total Funding Raised
$402M
Company Overview
AvenCell operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a Grant round in June 2025.
AvenCell is a biotechnology company that develops next-generation, switchable, allogeneic CAR-T cell immunotherapies for the treatment of hard-to-treat cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AvenCell Comparables
Compare AvenCell with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Wugen | 82% | |
| Bioheng Therapeutics | 81% | |
| Allogene Therapeutics | 81% |
For institutional investors. Book with your work email.
AvenCell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 30, 2025 | ||||
| Series B | Oct 22, 2024 | ||||
| Series A | Jun 22, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AvenCell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Grant |
| Cellex Cell Professionals GmbH | Series A |
| F-Prime Capital | Series B |
| Eight Roads Ventures | Series B |
| Novo Holdings | Series B |
| Eight Roads Ventures Japan | Series B |
| F-Prime Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2025
$40M grant received from Japan Agency for Medical Research and Development.
- Jun 30, 2025
Dual-antigen CAR-T therapy AVC203 for B-cell Lymphomas now at IND stage.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 6, 2026
AvenCell Therapeutics, Inc. forms in 2021 from contributed CAR-T programs to develop autologous and CRISPR/Cas-edited allogeneic CAR-T therapies.
- receives_financingSep 27, 2026
On Sep 24th '26, AvenCell Therapeutics, Inc. receives Ligand's commitment of up to $6M in Series C financing as part of a $47M agreement supporting its drug development programs.
For institutional investors. Book with your work email.
AvenCell Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AvenCell's valuation, stock price, and market status.
Is AvenCell a public or private company?
AvenCell is a private company.
What is the current stock price of AvenCell?
AvenCell is a private company, so its shares have no public market price. Caplight tracks AvenCell's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AvenCell worth (valuation)?
Valuation information for AvenCell is not publicly available.
Can I buy AvenCell stock?
AvenCell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AvenCell's last funding round?
AvenCell's most recent funding round was Grant on June 30, 2025.
Who are the main investors in AvenCell?
Key investors in AvenCell include Novo Holdings, Blackstone Life Sciences.
Will AvenCell IPO soon?
No public IPO plans have been announced for AvenCell.
How can I track AvenCell secondary market activity?
Caplight tracks bids, offers, and trades in AvenCell's shares on secondary markets.